Neurocrine Biosciences reports 28% jump in Q3 net sales, EPS beats estimates

Neurocrine Biosciences

28/10/2025 20:14

Overview

Neurocrine Q3 2025 net product sales rise 28% yr/yr to $790 mln

Adjusted EPS for Q3 2025 beats analysts' expectations

Adjusted net income for Q3 2025 exceeds analysts' estimates

Outlook

Neurocrine reaffirms full-year 2025 INGREZZA sales guidance at $2.5 bln to $2.55 bln

Company expects 2025 GAAP R&D expenses between $1 bln and $1.02 bln

Neurocrine anticipates 2025 GAAP SG&A expenses to range from $1.14 bln to $1.16 bln

Result Drivers

INGREZZA DEMAND - INGREZZA sales rose 12% yr/yr due to strong patient demand and record new prescriptions

CRENESSITY LAUNCH - CRENESSITY's strong launch driven by first-in-class status and 80% reimbursement coverage

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Adjusted EPS
Beat
$2.17
$1.58 (20 Analysts)
Q3 EPS
$2.04
Q3 Adjusted Net Income
Beat
$222.10 mln
$160.21 mln (18 Analysts)
Q3 Net Income
$209.50 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 25 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Neurocrine Biosciences Inc is $170.00, about 12.4% above its October 27 closing price of $148.94

The stock recently traded at 24 times the next 12-month earnings vs. a P/E of 25 three months ago

Press Release: ID:nPn3zH486a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)